FDA approves selinexor for treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Approval of this first-in-class, selective inhibitor of nuclear export was based on phase IIb SADAL study that showed a 29% overall response rate in a 134 patient trial. Marketing Authorization Application for this indication will be submitted to European Medicines Agency in 2021


Biospace Inc.